Exact Sciences Corporation

At this time, I would like to welcome everyone to the ExactScience's second quarter 2025 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. We do ask that today you limit yourself to one question. If you would like to withdraw your question, press star went again. Thank you. I would now like to turn the call over to Derek Lecow. Please go ahead.

Thank you for joining us for ExactScience's second quarter 2025 conference call. On the call today are Kevin Conroy, the company's chairman and CEO, and Aaron Bloomer, our chief financial officer. ExactScience has issued a press release earlier this afternoon, detailing our second quarter financial results. This news release and today's presentation are available on our website at ExactSciences.com. During today's call, we will make forward looking statements based on current expectations. Our actual results may be materially different from such statements. Discussions of non-GAAP figures and reconciliations to GAAP figures are available in our earnings press release and descriptions of the risks and uncertainties associated with ExactSciences are included in our SEC filings. Both can be accessed through our website. I'll now turn the call over to Kevin.

Thanks Derek. During the second quarter, the ExactSciences team delivered a record 1.3 million test results to patients, accelerated core revenue growth to 16% year over year and generated an all time high 138 million in adjusted EBITDA. As a result, we are raising guidance at midpoint for revenue by 55 million in adjusted EBITDA by 25 million. We also advanced our mission by expanding our agreement with two of our top 10 payers to make ColoGuard Plus in network. Entering an exclusive license with Freenome for blood-based colorectal cancer screening tests, gaining Medicare coverage for oncodetect our molecular residual disease test and announcing a multi-year productivity plan targeting 150 million in annual savings by 2026. Aaron will now review our second quarter results, updated guidance and multi-year productivity plan.